Bal, Christina and Stoshikj, Slagjana and Renner, Andreas and Milger, Katrin and Skowasch, Dirk and Schulz, Christian and Jandl, Margret and Schmidt, Olaf and Ehmann, Rainer and Zehetmayer, Sonja and Taube, Christian and Hamelmann, Eckard and Buhl, Roland and Korn, Stephanie and Idzko, Marco (2025) German Asthma Net: Characterisation of responders to anti-IL-5 and anti-IL-5(R) therapy. PULMONOLOGY, 31 (1): 2460868. ISSN 2531-0437,
Full text not available from this repository. (Request a copy)Abstract
IntroductionPrevious studies of anti-IL-5/IL-5(R) therapies in severe asthma found that response was mainly predicted by indicators of good baseline disease control. However, long-term response predictors remain unclear.MethodsResponders to anti-IL-5/IL-5(R) therapy in the well-characterised, real-life, international German Asthma Net (GAN) registry were analysed using regression analyses. Response was defined by >= 50% reduction in exacerbations or corticosteroid dose, super-response by a complete stop of both, and remission additionally by controlled asthma (ACT score >= 20).ResultsSeventy-seven percent of 347 patients (55% female, 56.6 +/- 12.3 years, follow-up 20.3 +/- 13 months) were responders and showed improved exacerbation rates, asthma control, and corticosteroid treatment reduction. Response was independently predicted by inhaled corticosteroid dose (odds ratio [OR] 1.5; p = 0.014), exacerbation rate (OR 1.2; p = 0.009), and treatment duration (OR 1.05, p = 0.023). Univariately, blood eosinophil counts notably predicted response (OR 12.4; p = 0.004). Super-response was inversely associated with corticosteroid dependence and depression. Remission was associated with the absence of systemic corticosteroids, better asthma control, and FEV1 in litre.ConclusionsThese results underscore that long-term anti-IL-5/IL-5(R) therapy reduces exacerbation and corticosteroid burden, especially in patients with severe disease and high type 2 inflammatory burden. Contrastingly, low baseline corticosteroid use and markers of good asthma control predicted remission and super-responder status.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BENRALIZUMAB EFFICACY; SUPER-RESPONDER; DOUBLE-BLIND; MEPOLIZUMAB; MULTICENTER; VALIDATION; ANTIBODY; Severe asthma; anti-IL-5/IL-5(R) therapy; responder; remission; biomarker |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Apr 2026 07:00 |
| Last Modified: | 20 Apr 2026 07:00 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67641 |
Actions (login required)
 |
View Item |
